Last reviewed · How we verify
NCT05070299
Developing a Psychosexual Educational Partners Program: PEPP A Feasibility Study
NA trial testing Psychosexual Educational Partner Program (PEPP) in Breast Cancer in 18 participants. Completed in 29 August 2022.
29 August 2022
Quick facts
| Lead sponsor | University of Michigan Rogel Cancer Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 18 |
| Start date | 15 March 2022 |
| Primary completion | 29 August 2022 |
| Estimated completion | 29 August 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Psychosexual Educational Partner Program (PEPP)
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Gynecologic Cancer — all drugs for Gynecologic Cancer →
Sponsor
University of Michigan Rogel Cancer Center
Who can join
18 and older, female only, with Breast Cancer or Gynecologic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single arm study to evaluate the feasibility, adherence, and usefulness of a psychosexual education partner program (PEPP) to improve partner communication and sexual function. This study is intended to get initial input from a small group of up to 10 women and their partners about the appropriateness, usefulness, and critical nature of the content as well as the feasibility and appeal of the method of delivery.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A Sexual Health Self-Management Intervention (Psychosexual Educational Partners Program) for Couples With a History of Breast and Gynecological Cancer: Mixed Methods Feasibility Study.
Arring NM, Reese JB, Lafferty C, Barton DL, et al · · 2025 · PMID 41118642 · DOI 10.2196/75743
Verify or expand the search:
- PubMed search for NCT05070299
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other University of Michigan Rogel Cancer Center trials
Trials by the same sponsor.
- NCT06914479 — Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and · Phase 1 · recruiting
- NCT07481344 — SunBeast: Evaluating UV Protective Behaviors and Education Interventions Among Ultrarunners · NA · not yet recruiting
- NCT07526545 — Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial · NA · not yet recruiting
- NCT07443943 — A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive · Phase 2 · recruiting
- NCT07365007 — A Virtually Delivered Diet Intervention (LASO-3) for the Improvement of Chemotherapy-Induced Peripheral Neuropathy in Ca · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05070299 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Michigan Rogel Cancer Center
- Last refreshed: 13 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05070299.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing